VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pseudo Biologist who wrote (4443)	3/20/1998 9:04:00 PM
From: scaram(o)uche	Read Replies (1) of 9719

PB: Genetic Systems.... Nowinski et al. (Genetic Systems -----> Oncogen) got good money for their shareholders, and Oncogen eventually became the Bristol-Myers Squibb Research Institute. Sorta depends on your perspective, but I'd say that the science established at Genetic Systems (Jeff Ledbetter and descendant studies with the likes of CTLA4) is still driving toward big utility in the clinic. Mark Lostrom, Ed Clark, Tony Siadak, Milt Tam.... the serologists at Genetic Systems were way out in front of those at Hybritech and Centocor. Cetus Immune had some good scientists, but they hit political snags with relatively ignorant management. Hybritech went belly up, smelling for a long time before doing such. Centocor was awful, and survived only because they hired a guy named Bob Jordan from Cutter/Bayer and a few other hard workers that turned things around. Cetus..... almost managed into the ground. Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next